About Recursion

Recursion is a clinical-stage biotechnology company using AI and automated lab experiments to discover new drugs at unprecedented speed and scale.

Investment Thesis

Public company with differentiated AI drug discovery platform

Why We Invested

  • Publicly traded with differentiated AI-powered drug discovery

  • Massive proprietary dataset from automated biology experiments

  • Pipeline spanning oncology, rare diseases, and infectious disease

  • Strategic partnership with NVIDIA for AI computing infrastructure

Key Metrics

$1.0B
Total Funding
$4B
Latest Valuation
13+
Years Active
501-1000
Team Size

Company Details

Legal Name Recursion Pharmaceuticals, Inc.
Industry Biotechnology
Sectors Biotechnology, Drug Discovery
Stage Late-stage
Founded 2013
Headquarters Salt Lake City, Utah, USA
Company Size 501-1000 employees

Investment Overview

Investment Thesis

Public company with differentiated AI drug discovery platform

Key Investment Factors

Market Opportunity

Recursion operates in the Biotechnology market, which is projected to grow significantly in the coming years.

Competitive Advantage

Proprietary technology and strong market position create significant barriers to entry.

Growth Strategy

Clear path to growth through market expansion, product development, and strategic acquisitions.

Financial Summary

$1.0B
Total Funding
$4B
Latest Valuation
Late-stage
Funding Stage
Jul 2023
Last Funding

Fund Information

Healthcare Innovation Fund

Open Innovation Fund

Investing in breakthrough healthcare technologies, biotechnology, digital health, and medical devices. This fund targets companies with potential to transform healthcare delivery and patient outcomes.

Invest in Recursion

$4B
Latest Valuation
1
Available Funds
Late-stage
Current Stage
$1.0B
Total Funding

Gain exposure to this high-growth company through our professionally managed funds. Our investment team has conducted extensive due diligence to identify promising opportunities.

Sign In to Invest